Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
NEW YORK, Jan. 29, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased GW Pharmaceuticals plc (Nasdaq:GWPH) securities between December 4, 2014 and January 8, 2016.
Click here to learn about the case: http://docs.wongesq.com/GWPH-Info-Request-Form-1080. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company lacked effective internal financial controls; (ii) the Company lacked effective controls over completeness and valuation of clinical trial accruals; and (iii) as a result of the foregoing, Defendants’ statements about GW Pharmaceuticals’ business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
In its 2015 Annual Report, GW Pharmaceuticals disclosed the discovery of a material weakness in its internal control over financial reporting for the year ended September 30, 2015. The Company noted that “management does not have sufficiently precise controls to evaluate the completeness and accuracy of the calculation of clinical trial accruals due to the incorrect allocation of expenditure to clinical studies.” On this news, GW Pharmaceuticals stock fell $3.55, or nearly 6%, to close at $56.31 per share on January 11, 2016.
If you suffered a loss in GW Pharmaceuticals you have until March 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/GWPH-Info-Request-Form-1080.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigation involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
